We've heard it all before: clients waking up one day in shock after discovering a coin-sized bald spot on their heads; women agonizing over the strands of hair they see on the shower floor; men looking for topical creams and shampoos to prevent the early onset of balding. Even more are tales of men and women on the search for the perfect wig or toupee to cover up the loss of their hair as a result of medication for a chronic illness.
In fact, the Japanese government has recently committed to establish a new approval process for regenerative medicine products focused on accelerating approval timelines. As it turns out, hair loss is a big concern in Asian countries. Buckler said some 21% of adult males and 6% of females in China suffer from hormone-driven hair loss.  And the International Society of Hair Restoration Surgery’s (ISHRS) biennial survey of hair restoration physicians found that the number of hair restoration patients in Asia increased 345% from 2004 to 2010.
Dupilumab is FDA approved for treating eczema aka atopic dermatitis and sold under the brand name Dupixent.  As the story goes, a patient with alopecia totalis (a form of areata which leaves a person’s head completely bald) was being treated for eczema by the drug Dupixent. After 6 weeks the patient first began to notice progress in terms of hair growth and at 7 months she had noticeable pigmented hair growth on her scalp. Notably, the patient stopped taking the dupilumab for a period of time and noticed her growth subsided; when she began taking the drug again the hair improved once more. This provides another useful therapy option for patients seeking treatment for AA. One would imagine a topical version would be worthwhile to investigate.
×